Costly Comorbidities Persist for the 90% of Patients With MASH and No Cirrhosis
MASH’s economic burden is substantial, particularly for patients with MASH and multiple comorbidities, even in the absence of cirrhosis.
Read More
MASH
Study Reveals MASLD, MetALD Responsible for One-Third of ICU Cirrhosis Cases
MASLD-related and MetALD-related cirrhosis is responsible for one-third of cirrhosis cases seen in the intensive care unit, according to a recent study.
Read More
New Definition of Steatotic Liver Disease Improves Prediction of Kidney Disease
A new classification links MASLD and ALD, based on metabolic dysfunction and alcohol use, with a significant risk of developing chronic kidney disease.
Read More
Study Identifies Genes in NASH-HCC Transformation
A study identified five genes— ME1, TP53I3, SOCS2, GADD45G, and CYP7A1— related to progression from non-alcoholic steatohepatitis to hepatocellular carcinoma.
Read More
HIIT + Energy Reduction Improves Liver Health in MASH
A combined intervention focusing on energy intake and interval training decreased body weight, fat mass, and liver injury in patients with MASH.
Read More
Study Identifies Most Accurate Noninvasive Method for Diagnosing MASH
A recent study compared the predictive performance of three imaging models in order to determine the most accurate noninvasive method for diagnosing MASH.
Read More
FIB-4 Scores Linked to Clinical & Economic Burden
High FIB-4 scores were linked to significantly greater healthcare resource utilization and costs among patients with MASH/NASH.
Read More
Evaluating Probiotics in Early MASH
A recent clinical trial showed that probiotic supplementation in patients with early-stage NASH/MASH did not significantly improve liver or clinical parameters.
Read More
Novel Biomarkers May Distinguish MASH From MASLD
A unique set of cytokine and chemokine markers could serve as biomarkers to differentiate non-alcoholic steatohepatitis from non-alcoholic fatty liver disease.
Read More
Exercise Improves Liver Biomarkers
Study findings suggest that exercise can mitigate liver fibrosis markers effectively, highlighting its role as a weight-neutral intervention supported by accessible biomarkers for widespread clinical use.
Read More
Cardiovascular Disease in MASH vs. Other Liver Diseases
The following is a summary of “Cardiovascular disease in patients with metabolic...
Read More